IPG 011
Alternative Names: IPG-011Latest Information Update: 05 Jan 2022
Price :
$50 *
At a glance
- Originator Nanjing Amifei Biopharmaceutical Technology
- Developer Immunophage Biotech; Nanjing Amifei Biopharmaceutical Technology
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Autoimmune disorders
Most Recent Events
- 16 Dec 2021 IPG 011 is available for licensing as of 16 Dec 2021. http://www.immunophage.com.cn/yanfaguanxian.html
- 16 Dec 2021 Early research in Autoimmune disorders in China (unspecified route) (Immunophage Biotech website, December 2021)